Webinar on Specialty Drugs and PBM Profits
Capital Rx’s Josh Golden, SVP, Strategy, examines the reasons behind the surge in specialty drug costs and how the PBM profit structure may be part of the problem, the eight ways a PBM can make money from a single specialty drug claim, and why biosimilars warrant heightened attention. View the webinar!
|